Capricor Therapeutics (CAPR) Receives Daily Media Sentiment Rating of 0.13

News articles about Capricor Therapeutics (NASDAQ:CAPR) have been trending somewhat positive on Thursday, Accern Sentiment reports. Accern rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Capricor Therapeutics earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 47.565501438857 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the headlines that may have effected Accern Sentiment’s rankings:

Capricor Therapeutics (NASDAQ:CAPR) traded down $0.06 during trading on Thursday, hitting $1.75. The stock had a trading volume of 225,589 shares, compared to its average volume of 652,584. The stock has a market cap of $44.48, a P/E ratio of -2.65 and a beta of -4.66. Capricor Therapeutics has a 52 week low of $0.63 and a 52 week high of $4.25.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.07. The firm had revenue of $0.31 million during the quarter, compared to analysts’ expectations of $1.00 million. The business’s revenue for the quarter was down 58.7% compared to the same quarter last year. During the same quarter last year, the business earned ($0.29) earnings per share. research analysts forecast that Capricor Therapeutics will post -0.54 earnings per share for the current fiscal year.

A number of brokerages have issued reports on CAPR. Zacks Investment Research lowered Capricor Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. HC Wainwright restated a “buy” rating and issued a $8.60 price objective (up from $6.50) on shares of Capricor Therapeutics in a report on Friday, January 26th.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Insider Buying and Selling by Quarter for Capricor Therapeutics (NASDAQ:CAPR)

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply